Comorbidities in patients with COPD and pulmonary rehabilitation: Do they matter?

European Respiratory Review

Volumn 23, Issue 131, 2014, Pages 131-141

  Franssen, Frits M E ^a   Rochester, Carolyn L ^b,c  

^a CIRO+ Center of Expertise for Chronic Organ Failure   (Netherlands)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; ENDURANCE TRAINING; EXERCISE INTENSITY; FUNCTIONAL STATUS; HUMAN; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PREVALENCE; PULMONARY REHABILITATION; QUALITY OF LIFE; RESISTANCE TRAINING; TREATMENT INDICATION;

COMORBIDITY; HUMANS; PATIENT SELECTION; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY THERAPY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84895469127     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007613     Document Type: Article

References (89)

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
2. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369: 448-457.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
4. Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer 2013; 13: 233-245.
5. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
6. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
7. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735.
8. Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes 2009; 7: 82.
9. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122: 348-355.
10. Sin DD. Is COPD really a cardiovascular disease? Chest 2009; 136: 329-330.
11. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009; 4: 337-349.
12. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 1208-1214.
13. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259-1265.
14. Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009; 179: 35-40.
15. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
16. Rutten FH, Moons KG, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005; 331: 1379.
17. Rutten FH, Vonken EJ, Cramer MJ, et al. Cardiovascular magnetic resonance imaging to identify left-sided chronic heart failure in stable patients with chronic obstructive pulmonary disease. Am Heart J 2008; 156: 506-512.
18. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531-1536.
19. Maltais F, LeBlanc P, Jobin J, et al. Peripheral muscle dysfunction in chronic obstructive pulmonary disease. Clin Chest Med 2000; 21: 665-677.
20. Agusti A, Soriano JB. COPD as a systemic disease. COPD 2008; 5: 133-138.
21. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.
22. Rutten EP, Breyer MK, Spruit MA, et al. Abdominal fat mass contributes to the systemic inflammation in chronic obstructive pulmonary disease. Clin Nutr 2010; 29: 756-760.
23. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999; 159: S1-S40.
24. Maltais F, LeBlanc P, Whittom F, et al. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax 2000; 55: 848-853.
25. Jørgensen NR, Schwarz P, Holme I, et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 2007; 101: 177-185.
26. Graat-Verboom L, Wouters EF, Smeenk FW, et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009; 34: 209-218.
27. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134: Suppl. 4, 43S-56S.
28. Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2001; 21: 80-86.
29. Grant I, Heaton RK, McSweeny AJ, et al. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 1982; 142: 1470-1476.
30. Liesker JJ, Postma DS, Beukema RJ, et al. Cognitive performance in patients with COPD. RespirMed 2004; 98: 351-356.
31. Rutten EP, Franssen FM, Spruit MA, et al. Anemia is associated with bone mineral density in chronic obstructive pulmonary disease. COPD 2013; 10: 286-292.
32. John M, Hoernig S, Doehner W, et al. Anemia and inflammation in COPD. Chest 2005; 127: 825-829.
33. Martinez-Rivera C, Portillo K, Muñoz-Ferrer A, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD 2012; 9: 243-250.
34. John M, Lange A, Hoernig S, et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol 2006; 111: 365-370.
35. Weitzenblum E, Chaouat A. Sleep and chronic obstructive pulmonary disease. Sleep Med Rev 2004; 8: 281-294.
36. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
37. Incalzi RA, Corsonello A, Pedone C, et al. Chronic renal failure: a neglected comorbidity of COPD. Chest 2010; 137: 831-837.
38. Casanova C, Baudet JS, del Valle Velasco M, et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 2004; 23: 841-845.
39. Kempainen RR, Savik K, Whelan TP, et al. High prevalence of proximal and distal gastroesophageal reflux disease in advanced COPD. Chest 2007; 131: 1666-1671.
40. Rascon-Aguilar IE, Pamer M, Wludyka P, et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 2006; 130: 1096-1101.
41. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
42. Powell HA, Iyen-Omofoman B, Baldwin DR, et al. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. J Thorac Oncol 2013; 8: 6-11.
43. Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010; 35: 1209-1215.
44. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease. A casecontrol study in a health maintenance organization. Arch Int Med 2000; 160: 2653-2658.
45. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627-643.
46. Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107: 1376-1384.
47. Giardino ND, Curtis JL, Andrei AC, et al. Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. Respir Res 2010; 11: 29.
48. Norwood R, Balkissoon R. Current perspectives on management of co-morbid depression in COPD. COPD 2005; 2: 185-193.
49. Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29: 923-929.
50. van Manen JG, Bindels PJ, Dekker EW, et al. Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med 2001; 95: 496-504.
51. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072-1079.
52. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
53. Lavie P, Herer P, Lavie L. Mortality risk factors in sleep apnoea: a matched case-control study. J Sleep Res 2007; 16: 128-134.
54. Lee R, McNicholas WT. Obstructive sleep apnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2011; 17: 79-83.
55. Schols AM, Broekhuizen R, Weling-Scheepers CA, et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82: 53-59.
56. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society Statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-e64.
57. Nici L, Zuwallack R. Scope, background and definition of pulmonary rehabilitation. Eur J Phys Rehabil Med 2011; 47: 465-474.
58. Carreiro A, Santos J, Rodrigues F. [Impact of comorbidities in pulmonary rehabilitation outcomes in patients with chronic obstructive pulmonary disease]. Rev Port Pneumol 2013; 19: 106-113.
59. Crisafulli E, Costi S, Luppi F, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63: 487-492.
60. Crisafulli E, Gorgone P, Vagaggini B, et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. Eur Respir J 2010; 36: 1042-1048.
61. Garrod R, Marshall J, Barley E, et al. Predictors of success and failure in pulmonary rehabilitation. Eur Respir J 2006; 27: 788-794.
62. Greening NJ, Evans RA, Williams JE, et al. Does body mass index influence the outcomes of a Waking-based pulmonary rehabilitation programme in COPD? Chron Respir Dis 2012; 9: 99-106.
63. von Leupoldt A, Taube K, Lehmann K, et al. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. Chest 2011; 140: 730-736.
64. Ramachandran K, McCusker C, Connors M, et al. The influence of obesity on pulmonary rehabilitation outcomes in patients with COPD. Chron Respir Dis 2008; 5: 205-209.
65. Vagaggini B, Costa F, Antonelli S, et al. Clinical predictors of the efficacy of a pulmonary rehabilitation programme in patients with COPD. Respir Med 2009; 103: 1224-1230.
66. Walsh JR, McKeough ZJ, Morris NR, et al. Metabolic disease and participant age are independent predictors of response to pulmonary rehabilitation. J Cardiopulm Rehabil Prev 2013; 33: 249-256.
67. Young P, Dewse M, Fergusson W, et al. Respiratory rehabilitation in chronic obstructive pulmonary disease: predictors of nonadherence. Eur Respir J 1999; 13: 855-859.
68. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
69. McNamara RJ, McKeough ZJ, McKenzie DK, et al. Water-based exercise in COPD with physical comorbidities: a randomised controlled trial. Eur Respir J 2013; 41: 1284-1291.
70. Tan KH, De Cossart L, Edwards PR. Exercise training and peripheral vascular disease. Br J Surg 2000; 87: 553-562.
71. Bennell KL, Hinman RS. A review of the clinical evidence for exercise in osteoarthritis of the hip and knee. J Sci Med Sport 2011; 14: 4-9.
72. O'Gorman DJ, Krook A. Exercise and the treatment of diabetes and obesity. Med Clin North Am 2011; 95: 953-969.
73. Rees K, Taylor RS, Singh S, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2004; 3: CD003331.
74. Spruit MA, Eterman RM, Hellwig VA, et al. Effects of moderate-to-high intensity resistance training in patients with chronic heart failure. Heart 2009; 95: 1399-1408.
75. Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr 2002; 21: 1-14.
76. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
77. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; 3: CD002968.
78. Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005; 25: 226-232.
79. Vivodtzev I, Minet C, Wuyam B, et al. Significant improvement in arterial stiffness after endurance training in patients with COPD. Chest 2010; 137: 585-592.
80. Cavalcante JL, Lima JA, Redheuil A, et al. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 2011; 57: 1511-1522.
81. Gale NS, Duckers JM, Enright S, et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med 2011; 11: 20.
82. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362-368.
83. Güell R, Resqueti V, Sangenis M, et al. Impact of pulmonary rehabilitation on psychosocial morbidity in patients with severe COPD. Chest 2006; 129: 899-904.
84. Coventry PA, Hind D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: systematic review and meta-analysis. J Psychosom Res 2007; 63: 551-565.
85. Vanfleteren LE, Franssen FM, Uszko-Lencer NH, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol 2011; 108: 1669-1674.
86. Janssen DJ, Spruit MA, Leue C, et al. Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Chron Respir Dis 2010; 7: 147-157.
87. Working Group on Cardiac Rehabilitation and Exercise Physiology, Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise training in chronic heart failure patients. Eur Heart J 2001; 22: 125-135.
88. Myers J. Principles of exercise prescription for patients with chronic heart failure. Heart Fail Rev 2008; 13: 61-68.
89. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-1894.